Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19

Nezulcitinib (TD‐0903), a lung‐selective pan–Janus‐associated kinase (JAK) inhibitor designed for inhaled delivery, is under development for treatment of acute lung injury associated with coronavirus disease 2019 (COVID‐19). This two‐part, double‐blind, randomized, placebo‐controlled, single ascendi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfeifer, Nathan D., Lo, Arthur, Bourdet, David L., Colley, Kenneth, Singh, Dave
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444931/
https://www.ncbi.nlm.nih.gov/pubmed/34318597
http://dx.doi.org/10.1111/cts.13123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444931/
https://www.ncbi.nlm.nih.gov/pubmed/34318597
http://dx.doi.org/10.1111/cts.13123

Ejemplares similares